AUG 14, 2018 11:20 PM PDT

New Drug for Refractory Cutaneous T-cell Lymphoma

WRITTEN BY: Mauri Brueggeman

There are two types of cutaneous T-cell lymphoma, or CTCL, which fall under the non-Hodgkin’s Lymphoma umbrella; Mycosis Fungoides (MF) presents with skin patches or tumorous plaques and Sezary Syndrome (SS) presents with a thin itchy rash and must also involve lymphoma cells in the bloodstream.  CTCL is one of the most common types of T-cell lymphoma.  Current treatment options include both topical and systemic therapies depending on the extent of disease at the time of diagnosis.  While many patients can complete traditional treatment and live healthy lives, there are a subset of patients with relapsed or refractory disease which becomes harder to treat.  This group of patients have not had many options until now.  The FDA has just recently approved a new drug called mogamulizumab-kpkc (Poteligeo, Kyowa Hakko Kirin Pharma), which is specific for MF and SS which are harder to treat types of non-Hodgkin’s lymphoma. 

Mogamulizumab-kpkc is a directed monoclonal antibody that binds to a specific chemokine receptor, CCR4.  This receptor expression is found on cells involved in our innate and adaptive immune systems and has been documented as a present marker in CTCL.  A large phase III clinical trial (NCT01728805) compared this drug mogamulizumab-kpkc, named KW-0761, with the current vorinostat (Zolinza, Merck) therapy for CTCL.  The study involved 372 participants across the United States, Australia, multiple countries in Europe, and Japan.  Progression free survival was significant for those participants receiving KW-0761.  While there were some adverse reactions reported, the drug is a breakthrough and Cfills a needed gap for patients with these types of T-cell lymphomas. 

Mogamulizumab acts by reducing the number of CCR4-expressing cells through the well described process of antibody dependent, cell-mediated cytotoxicity.  This is an immune system response using Fc receptor effector cells which recognize and destroy targeted cells identified by the specific antibodies covering their pathogenic antigens.  In this case, the pathogenic antigen is CCR4.  The antibody dependent, cell-mediated cytotoxicity pathway utilizes cytotoxic granule release and is already used in the body for protection against infectious diseases.  The model for monoclonal antibody use in cancer therapy has been proven effective over the past few years of research and clinical application.

Sources: FDA, Lymphoma Research Foundation, Blood, Academic Press,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu...
FEB 05, 2020
Genetics & Genomics
FEB 05, 2020
'Chromosome Shattering' is Common Across Cancer Types
A type of genetic mutation called chromothripsis was discovered a few years ago in chronic lymphocytic leukemia....
FEB 12, 2020
Cancer
FEB 12, 2020
Can we eradicate cervical cancer within a century?
Two studies recently published in The Lancet present evidence that the eradication of cervical cancer could be possible within the next century. The World ...
FEB 11, 2020
Cancer
FEB 11, 2020
Could we be over-diagnosing cancer?
Roughly one in every two people are estimated to receive a cancer diagnosis at some point in their lives, but are all of those diagnoses valid? New researc...
FEB 19, 2020
Technology
FEB 19, 2020
Novel Technology Analyzes Single Cancer Cells
Recent technology may help for the first time to enable cancer scientists the analysis of individual behavior of millions of different cells living inside ...
FEB 24, 2020
Health & Medicine
FEB 24, 2020
Breast Cancer Screening, without the Radiation
Researchers from the University of Waterloo have developed a prototype of a novel technology that is capable of screening for breast cancer without using r...
Loading Comments...